Theriva Biologics, Inc. — Form 8-K Summary
Reporting date: October 30, 2026; filed November 2, 2026. This current report concerns the completed sale of specified product assets, not a periodic financial-results report.
Transaction and business context
On October 30, Theriva sold Biossil Labs Inc. assets relating primarily to SYN-004 (ribaxamase), including SYN-007, and certain SYN-006 assets. The closing occurred when the agreement was signed. Biossil controls development and commercialization and must use commercially reasonable efforts to develop and seek approval for at least one product. Theriva retains assets and liabilities not expressly transferred, including liabilities arising before closing, and granted Biossil a limited license to certain retained intellectual property needed to exploit the products.
Financial terms and impact
- Biossil paid Theriva a non-refundable, non-creditable upfront payment of $350,000 at closing.
- Theriva may receive up to $3 million in regulatory milestones and up to $88 million in sales milestones, each payable only once under the specified conditions.
- Theriva is eligible for low-single-digit royalties on worldwide net sales, subject to a $250 million cap, and low-double-digit payments on certain license consideration; the latter payments are not subject to the royalty cap.
- At closing, Theriva paid PREV ABR LLC $140,000 under an amendment to a prior agreement. Theriva must also pay PREV 50% of qualifying milestone payments, 33⅓% of royalties, and 50% of other qualifying consideration, subject to an aggregate $13 million cap that includes the closing payment and certain other specified payments.
- The filing does not provide a clear value for the transaction’s net proceeds after the PREV payment and any other costs. It provides no revenue, profit, cash-flow, margin, debt, or liquidity results, and no comparable-period financial data.
Material changes, risks, and contingencies
- The disposition transfers specified product assets and future development and commercialization control to Biossil. No change to Theriva’s overall financial results or remaining business is quantified in this filing.
- Future milestone, royalty, and license payments are uncertain. The company cautions that Biossil may not successfully develop, obtain regulatory approval for, or commercialize any product, and Theriva may receive no amounts beyond the upfront payment.
- The agreement does not provide for transaction termination or asset reversion following a post-closing breach; remedies principally include indemnification, specific performance, and dispute resolution. Biossil may offset certain finally determined indemnification amounts against payments due to Theriva, but not against the upfront payment.
- Theriva agreed to provide transition assistance for 120 days. Biossil assumed only specified post-closing liabilities; Theriva retained other liabilities, including pre-closing liabilities.
Key facts for investors to verify
- Whether Biossil advances the products through development and regulatory review, and whether any milestone or commercial-sale triggers are achieved.
- The precise royalty, milestone, and license-payment calculations and how the PREV sharing terms and $13 million cap apply to future receipts.
- Theriva’s actual net cash proceeds and any related costs or retained liabilities, which are not fully quantified in this 8-K.
- The full agreement terms, including provisions in omitted confidential schedules and exhibits; the filing states that the agreement descriptions are qualified by the filed agreements.